Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Recommendation of “Buy” from Analysts

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) has earned an average recommendation of “Buy” from the thirteen research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, ten have given a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $37.70.

CNTA has been the subject of several research reports. Stephens assumed coverage on Centessa Pharmaceuticals in a report on Tuesday, October 28th. They issued an “overweight” rating and a $35.00 target price for the company. Lifesci Capital raised shares of Centessa Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, September 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, October 27th. Finally, Wells Fargo & Company upped their price target on shares of Centessa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, CTO Tia L. Bush sold 40,000 shares of the company’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $26.00, for a total transaction of $1,040,000.00. Following the completion of the sale, the chief technology officer owned 121,503 shares in the company, valued at $3,159,078. This represents a 24.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mario Alberto Accardi sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction on Monday, December 8th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the completion of the transaction, the insider owned 178,801 shares in the company, valued at $5,364,030. This represents a 5.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 99,000 shares of company stock valued at $2,514,460 over the last 90 days. Corporate insiders own 7.09% of the company’s stock.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in CNTA. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Centessa Pharmaceuticals by 15,209.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company’s stock valued at $46,000 after buying an additional 3,194 shares in the last quarter. Osterweis Capital Management Inc. purchased a new stake in Centessa Pharmaceuticals during the first quarter valued at approximately $47,000. Fox Run Management L.L.C. acquired a new stake in Centessa Pharmaceuticals in the first quarter valued at approximately $160,000. Vestal Point Capital LP acquired a new stake in Centessa Pharmaceuticals in the first quarter valued at approximately $214,000. Finally, Campbell & CO Investment Adviser LLC purchased a new position in Centessa Pharmaceuticals in the second quarter worth $218,000. 82.01% of the stock is currently owned by institutional investors.

Centessa Pharmaceuticals Price Performance

Centessa Pharmaceuticals stock opened at $24.85 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57. The stock has a market cap of $3.34 billion, a price-to-earnings ratio of -13.58 and a beta of 1.55. The firm has a 50-day moving average of $25.83 and a two-hundred day moving average of $20.11. Centessa Pharmaceuticals has a 1 year low of $9.60 and a 1 year high of $30.58.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). On average, research analysts forecast that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical?stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision?making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.